Abstract 4129675: Effective Transcatheter Intracoronary Delivery of mRNA-Lipid Nanoparticle Targeting on The Heart
Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and effective mRNA delivery system. However, effectively delivering LNPs to the heart remains a significant challenge. We evaluated the efficacy...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 150; no. Suppl_1; p. A4129675 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
12.11.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and effective mRNA delivery system. However, effectively delivering LNPs to the heart remains a significant challenge. We evaluated the efficacy of transcatheter intracoronary (IC) administration compared to intravenous (IV) and intramyocardial (IM) administration as methods for delivering.
Methods: Normal rabbits were used to examine each route of administration. Fluorescence (ATTO 700)-labeled LNP encapsulating Firefly Luciferase (FLuc) mRNA (25 ug/kg) were used to confirm the in vivo mRNA-LNP dynamics. The LNP accumulation and FLuc expression were verified using an in vivo imaging system (IVIS) 4 hours post-administration, followed by immunohistochemical analysis. The same experiments were conducted in an ischemia-reperfusion (I/R) model.
Results: In the normal model, IVIS spectrum data showed that LNPs accumulated in the order of IM, IC and IV groups, with FLuc expression significantly higher in the IC group than in the IV group and comparable to the IM group (A). Histological analysis revealed that FLuc-expressing cells were mainly found in troponin T-positive cardiomyocytes at the injection site in the IM group and throughout the heart in the IC group (B). In the I/R model, LNP accumulation and FLuc expression were increased in the IV group compared to the normal model, whereas, in the IC and IM groups LNP accumulation and FLuc expression levels were similar to those in the normal model (C). Histological analysis revealed more FLuc-expressing cells in the infarcted area in all groups, but higher FLuc expression was observed in remote areas in the IC group (D).
Conclusions: IC administration effectively delivered mRNA-LNPs not only to the damaged area but also to the remote area (non-damaged area) in the diseased heart, suggesting a safe and useful method for delivery to a wider range of cardiomyocytes in the heart. |
---|---|
AbstractList | Abstract only Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and effective mRNA delivery system. However, effectively delivering LNPs to the heart remains a significant challenge. We evaluated the efficacy of transcatheter intracoronary (IC) administration compared to intravenous (IV) and intramyocardial (IM) administration as methods for delivering. Methods: Normal rabbits were used to examine each route of administration. Fluorescence (ATTO 700)-labeled LNP encapsulating Firefly Luciferase (FLuc) mRNA (25 ug/kg) were used to confirm the in vivo mRNA-LNP dynamics. The LNP accumulation and FLuc expression were verified using an in vivo imaging system (IVIS) 4 hours post-administration, followed by immunohistochemical analysis. The same experiments were conducted in an ischemia-reperfusion (I/R) model. Results: In the normal model, IVIS spectrum data showed that LNPs accumulated in the order of IM, IC and IV groups, with FLuc expression significantly higher in the IC group than in the IV group and comparable to the IM group (A). Histological analysis revealed that FLuc-expressing cells were mainly found in troponin T-positive cardiomyocytes at the injection site in the IM group and throughout the heart in the IC group (B). In the I/R model, LNP accumulation and FLuc expression were increased in the IV group compared to the normal model, whereas, in the IC and IM groups LNP accumulation and FLuc expression levels were similar to those in the normal model (C). Histological analysis revealed more FLuc-expressing cells in the infarcted area in all groups, but higher FLuc expression was observed in remote areas in the IC group (D). Conclusions: IC administration effectively delivered mRNA-LNPs not only to the damaged area but also to the remote area (non-damaged area) in the diseased heart, suggesting a safe and useful method for delivery to a wider range of cardiomyocytes in the heart. Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and effective mRNA delivery system. However, effectively delivering LNPs to the heart remains a significant challenge. We evaluated the efficacy of transcatheter intracoronary (IC) administration compared to intravenous (IV) and intramyocardial (IM) administration as methods for delivering. Methods: Normal rabbits were used to examine each route of administration. Fluorescence (ATTO 700)-labeled LNP encapsulating Firefly Luciferase (FLuc) mRNA (25 ug/kg) were used to confirm the in vivo mRNA-LNP dynamics. The LNP accumulation and FLuc expression were verified using an in vivo imaging system (IVIS) 4 hours post-administration, followed by immunohistochemical analysis. The same experiments were conducted in an ischemia-reperfusion (I/R) model. Results: In the normal model, IVIS spectrum data showed that LNPs accumulated in the order of IM, IC and IV groups, with FLuc expression significantly higher in the IC group than in the IV group and comparable to the IM group (A). Histological analysis revealed that FLuc-expressing cells were mainly found in troponin T-positive cardiomyocytes at the injection site in the IM group and throughout the heart in the IC group (B). In the I/R model, LNP accumulation and FLuc expression were increased in the IV group compared to the normal model, whereas, in the IC and IM groups LNP accumulation and FLuc expression levels were similar to those in the normal model (C). Histological analysis revealed more FLuc-expressing cells in the infarcted area in all groups, but higher FLuc expression was observed in remote areas in the IC group (D). Conclusions: IC administration effectively delivered mRNA-LNPs not only to the damaged area but also to the remote area (non-damaged area) in the diseased heart, suggesting a safe and useful method for delivery to a wider range of cardiomyocytes in the heart. |
Author | Kawamura, Masashi Matsuzaki, Takashi Saito, Shunsuke Sasai, Masao Hirano, Kunio Fujishiro, Anri Handa, Kazuma Miki, Kenji Fujimura, Lisa Miyagawa, Shigeru Tsuneda, Ryo Harada, Akima |
Author_xml | – sequence: 1 givenname: Kazuma surname: Handa fullname: Handa, Kazuma organization: Osaka University, Osaka, Japan – sequence: 2 givenname: Masashi surname: Kawamura fullname: Kawamura, Masashi organization: Osaka University, Osaka, Japan – sequence: 3 givenname: Masao surname: Sasai fullname: Sasai, Masao organization: OSAKA UNIVERSITY, Osaka, Japan – sequence: 4 givenname: Takashi surname: Matsuzaki fullname: Matsuzaki, Takashi organization: Osaka University, Osaka, Japan – sequence: 5 givenname: Akima surname: Harada fullname: Harada, Akima organization: Osaka University, Osaka, Japan – sequence: 6 givenname: Kenji surname: Miki fullname: Miki, Kenji organization: Osaka Univerisy, Suita, Osaka, Japan – sequence: 7 givenname: Lisa surname: Fujimura fullname: Fujimura, Lisa organization: Osaka University, Osaka, Japan – sequence: 8 givenname: Shunsuke surname: Saito fullname: Saito, Shunsuke organization: Osaka University Graduate School of Medicine, Suita, Osaka, Japan – sequence: 9 givenname: Ryo surname: Tsuneda fullname: Tsuneda, Ryo organization: Terumo Corporation, Innovation Center, Kanagawa, Japan – sequence: 10 givenname: Anri surname: Fujishiro fullname: Fujishiro, Anri organization: Terumo Corporation, Innovation Center, Kanagawa, Japan – sequence: 11 givenname: Kunio surname: Hirano fullname: Hirano, Kunio organization: Terumo Corporation, Innovation Center, Kanagawa, Japan – sequence: 12 givenname: Shigeru surname: Miyagawa fullname: Miyagawa, Shigeru organization: Osaka university graduate school, Suita Osaka, Japan |
BookMark | eNqFkNFOwjAUhhuDiYC-Q19gs11X1hlvCKKQEEwMXjddd8amo13aIvHtLYF7r05P_v9r2m-CRsYaQAhTklI6o4-6czqlnKT-OAy9pGlOs3JW8Bs0pjzLk5yzcoTGhJAyKViW3aGJ919xnbGCj5GbVz44pQO-ck942TSgQ_cDeOeU8VqFFgI4vDbnonXWKPeLX6CPlXiwDT58bOfJphu6Gm-VsYNyodN95JXbQ-jMHluDdy3gFcToHt02qvfwcJ1T9Pm63C1Wyeb9bb2YbxJNScaTAhRnTBBglDLFMlrrQlSECKG0IKrMq7oCVnGlakoY16UQpOYFrWNR6RhNkbjcq5313kEjB9cd4tslJfLsTp7dyehOXt3Jq4OIPl_Qk-3j1_13fzyBky2oPrT_43_1R3zW |
ContentType | Journal Article |
Copyright | 2024 by American Heart Association, Inc. |
Copyright_xml | – notice: 2024 by American Heart Association, Inc. |
DBID | AAYXX CITATION |
DOI | 10.1161/circ.150.suppl_1.4129675 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | A4129675 |
ExternalDocumentID | 10_1161_circ_150_suppl_1_4129675 AHA_2023_4129675 |
Genre | meeting-abstract |
GroupedDBID | --- .-D .3C .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPMR ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACLDA ACOAL ACRKK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADCYY ADGGA ADHPY AE6 AEBDS AENEX AFBFQ AFCHL AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BYPQX C45 CS3 DIK DIWNM DU5 E3Z EBS EEVPB ERAAH EX3 F2K F2L F2M F2N F5P FCALG GNXGY GQDEL H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 K-A K-F K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B O9- OAG OAH OBH OCB ODMTH OGEVE OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M WH7 WOQ WOW X3V X3W XXN XYM YFH YOC YSK YYM YZZ ZFV ZY1 ~H1 AAFWJ AAYXX ABPXF CITATION |
ID | FETCH-LOGICAL-c1025-7ea53380e3113a321dc78b0088ac80a94bdbe3b5aad1035c9880d571d1dcacbe3 |
ISSN | 0009-7322 |
IngestDate | Thu Jul 03 08:28:00 EDT 2025 Wed Apr 16 02:26:58 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl_1 |
IssueTitle | Abstracts From the American Heart Association's 2024 Scientific Sessions and the American Heart Association's 2024 Resuscitation Science Symposium |
Keywords | Coronary circulation Nucleosides and nucleotides Ischemia reperfusion Drug administration |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1025-7ea53380e3113a321dc78b0088ac80a94bdbe3b5aad1035c9880d571d1dcacbe3 |
Notes | Author Disclosures: For author disclosure information, please visit the AHA Scientific Sessions website. |
ParticipantIDs | crossref_primary_10_1161_circ_150_suppl_1_4129675 wolterskluwer_health_10_1161_circ_150_suppl_1_4129675 |
PublicationCentury | 2000 |
PublicationDate | 2024-November-12 2024-11-12 |
PublicationDateYYYYMMDD | 2024-11-12 |
PublicationDate_xml | – month: 11 year: 2024 text: 2024-November-12 day: 12 |
PublicationDecade | 2020 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAbbrev | Circulation |
PublicationYear | 2024 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
SSID | ssj0006375 |
Score | 2.4642167 |
Snippet | Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an established and... Abstract only Introduction: mRNA has great potential to provide new medical innovations in the treatment of heart failure. Lipid nanoparticles (LNPs) are an... |
SourceID | crossref wolterskluwer |
SourceType | Index Database Publisher |
StartPage | A4129675 |
Title | Abstract 4129675: Effective Transcatheter Intracoronary Delivery of mRNA-Lipid Nanoparticle Targeting on The Heart |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1161/circ.150.suppl_1.4129675 |
Volume | 150 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdZB2MwxtZurPtCD2MvwVlk-XNvodvIVlrYSKFvRpJlKG3tkdiU5o_q37g7SbbjktGtLyZRbCn2_XynO_10R8gHBXq_8AvhYXpzLwCb40mtQ49hcquC5_ACmmyfx9H8JPhxGp6ORjcbrKWmlhO13rqv5D5ShTaQK-6S_Q_Jdp1CA3wG-cIRJAzHf5LxTGKgQtXjAOwpzMnRvbfpiJEPZMyQScuKiRC_YxRXYb4C5Ml90RdIyLDL67-OZx7WsM5R14ITbQcaLwxJ3LCiS8PMmOtbGZEOzpbKlf_aVtVnI8owx4CFZW-sm94UHIorcdmYUkfjI7HCwk5dyAe-nrXtVR84r1fNWtha2wtx3l3hAhd-gDv4mD9QxqkXc7steaKd_oXzgtDmN-oUtE1N65Boqp1mbLv6j1D9K7j5CVwE5secOnFC6E1eu8x_yxJ2_ETjGUUsw54y6ClzPWWupwfkoQ9uCerVw599dvqIx2FbuQ9vrGWORezT3_7TYDr05KpCisTq3OyQ2JjnLJ6Rp85BoTMLgudkpMtdsjcrRV1dXtOP1FCGzVrMLnl05JgZe2TZYpG6IT_TDol0gEQ6QCJtkUirgvZIpJtIpB0SaVVSQCI1SHxBTr59XRzMPVfPw1PMVE3WApyLZKo5Y1xwn-UqTkDtJ4lQyVSkgcyl5jIUImdTHqoUbEsexiyHE4WCn16SnbIq9StCdeLzMNJaJqIIeBLKRBcanB8pY67TNN4nrH2s2W-btiW7S6j7JBw8_8zuRL7zutf3GOsNedy_Em_JTr1s9DuY3dbyvYHUH8E2pSk |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+4129675%3A+Effective+Transcatheter+Intracoronary+Delivery+of+mRNA-Lipid+Nanoparticle+Targeting+on+The+Heart&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Handa%2C+Kazuma&rft.au=Kawamura%2C+Masashi&rft.au=Sasai%2C+Masao&rft.au=Matsuzaki%2C+Takashi&rft.date=2024-11-12&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=150&rft.issue=Suppl_1&rft_id=info:doi/10.1161%2Fcirc.150.suppl_1.4129675&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_circ_150_suppl_1_4129675 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |